Matches in SemOpenAlex for { <https://semopenalex.org/work/W2282157035> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2282157035 abstract "Purpose HER2-positive breast cancer accounts for more than 20% of the diagnosed cases and is characterized by aggressive growth, increased disease recurrence, and poor prognosis. While much of the signaling mechanism(s) have been elucidated, the impact of HER2 positivity on cellular metabolism is not well understood. We examined (1) gene expression profiles of mammalian breast cancer cell lines with increasing HER2 expression levels (MCF10A, MDA-MB-468, MDA-MB-453, HCC1954, HCC2218) and correlated changes to metabolic expression profiles and (2) the effect of serum starvation and pervanadate treatment on the metabolic profiles of these HER2-expressing cell lines. Methods Our study used a combination of 1H-NMR and 2D-NMR (TOCSY), multivariate analyses, and protein expression validation in human breast cancer cell lines (untreated, serum-starved, serum-starved with pervanadate treatment). Results We found that both gene and metabolic expression profiles of HER2-positive cell lines correlated with leucine and isoleucine biosynthesis (p-value < 0.05). Comparative analyses of profiles from untreated, serum-starved, and serum-starved with pervanadate-treated cell samples revealed that lactate concentration (p-value <0.05) dropped significantly with serum starvation and pervanadate treatment consistent with reduced glycolytic metabolism and potentially mediated through suppression of tyrosine phosphatase activity. Conclusion This study highlights important metabolites that are potential biomarkers of HER2-positive breast cancer and suggests alternate/novel pathways to consider for future understanding and treatment. Support or Funding Information This work was funded in part through intramural programs at Fresno State to MKS and JAB, and through the NIGMS 1SC3GM122630-01 to JAB. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal." @default.
- W2282157035 created "2016-06-24" @default.
- W2282157035 creator A5038007841 @default.
- W2282157035 creator A5042330763 @default.
- W2282157035 creator A5047927355 @default.
- W2282157035 creator A5061404761 @default.
- W2282157035 creator A5081633215 @default.
- W2282157035 date "2018-04-01" @default.
- W2282157035 modified "2023-10-16" @default.
- W2282157035 title "Metabolomic Analysis of HER2‐positive Breast Cancer Cells" @default.
- W2282157035 doi "https://doi.org/10.1096/fasebj.2018.32.1_supplement.658.10" @default.
- W2282157035 hasPublicationYear "2018" @default.
- W2282157035 type Work @default.
- W2282157035 sameAs 2282157035 @default.
- W2282157035 citedByCount "0" @default.
- W2282157035 crossrefType "journal-article" @default.
- W2282157035 hasAuthorship W2282157035A5038007841 @default.
- W2282157035 hasAuthorship W2282157035A5042330763 @default.
- W2282157035 hasAuthorship W2282157035A5047927355 @default.
- W2282157035 hasAuthorship W2282157035A5061404761 @default.
- W2282157035 hasAuthorship W2282157035A5081633215 @default.
- W2282157035 hasConcept C104317684 @default.
- W2282157035 hasConcept C121608353 @default.
- W2282157035 hasConcept C126322002 @default.
- W2282157035 hasConcept C134018914 @default.
- W2282157035 hasConcept C1491633281 @default.
- W2282157035 hasConcept C150194340 @default.
- W2282157035 hasConcept C170493617 @default.
- W2282157035 hasConcept C21565614 @default.
- W2282157035 hasConcept C502942594 @default.
- W2282157035 hasConcept C530470458 @default.
- W2282157035 hasConcept C55493867 @default.
- W2282157035 hasConcept C60644358 @default.
- W2282157035 hasConcept C71924100 @default.
- W2282157035 hasConcept C85528070 @default.
- W2282157035 hasConcept C86803240 @default.
- W2282157035 hasConcept C96232424 @default.
- W2282157035 hasConceptScore W2282157035C104317684 @default.
- W2282157035 hasConceptScore W2282157035C121608353 @default.
- W2282157035 hasConceptScore W2282157035C126322002 @default.
- W2282157035 hasConceptScore W2282157035C134018914 @default.
- W2282157035 hasConceptScore W2282157035C1491633281 @default.
- W2282157035 hasConceptScore W2282157035C150194340 @default.
- W2282157035 hasConceptScore W2282157035C170493617 @default.
- W2282157035 hasConceptScore W2282157035C21565614 @default.
- W2282157035 hasConceptScore W2282157035C502942594 @default.
- W2282157035 hasConceptScore W2282157035C530470458 @default.
- W2282157035 hasConceptScore W2282157035C55493867 @default.
- W2282157035 hasConceptScore W2282157035C60644358 @default.
- W2282157035 hasConceptScore W2282157035C71924100 @default.
- W2282157035 hasConceptScore W2282157035C85528070 @default.
- W2282157035 hasConceptScore W2282157035C86803240 @default.
- W2282157035 hasConceptScore W2282157035C96232424 @default.
- W2282157035 hasFunder F4320337354 @default.
- W2282157035 hasIssue "S1" @default.
- W2282157035 hasLocation W22821570351 @default.
- W2282157035 hasOpenAccess W2282157035 @default.
- W2282157035 hasPrimaryLocation W22821570351 @default.
- W2282157035 hasRelatedWork W1994481196 @default.
- W2282157035 hasRelatedWork W2003213334 @default.
- W2282157035 hasRelatedWork W2007867899 @default.
- W2282157035 hasRelatedWork W2009966535 @default.
- W2282157035 hasRelatedWork W2028564053 @default.
- W2282157035 hasRelatedWork W2056036087 @default.
- W2282157035 hasRelatedWork W2063082931 @default.
- W2282157035 hasRelatedWork W2089295326 @default.
- W2282157035 hasRelatedWork W2129462573 @default.
- W2282157035 hasRelatedWork W2164347610 @default.
- W2282157035 hasVolume "32" @default.
- W2282157035 isParatext "false" @default.
- W2282157035 isRetracted "false" @default.
- W2282157035 magId "2282157035" @default.
- W2282157035 workType "article" @default.